The Battle of the Giants Expands: Vac Maker VS Vac Maker

http://ilena-rosenthal.blogspot.com
http://ilena-rosenthal.blogspot.com/...cer-while.html


We've been waiting for this time!


Merck has been going whole hog spending billions PRing & advertising
it's Gardasil on every level possible.

His usenet flacks use their scare tactics and trivialize the risks and
unknowns, calling a vastly complicated and complex issue "simple
math."

They are attempting to sell as many of their $120 jabs (advising a
minimum of 3) as possible before the dangers surfaced into the media
and their rival came out to fight for it's right to sell their own
version of a wildly profitable, unproven drug.

Well ... now it's the Giants against each other ... a veritable flack
wonderland. They can start 'double dipping' in the HPV department and
fuel the Vac Maker Wars.

http://money.cnn.com/news/newsfeeds/...1_FORTUNE5.htm

UK Regulator: GSK Cervarix Announcement Wasn't Promotional

September 11, 2007: 10:51 AM EST


LONDON -(Dow Jones)- The U.K.'s drug regulator Tuesday said it
concluded that a GlaxoSmithkline PLC (GSK) press release about the
drug maker's experimental cervical-cancer vaccine Cervarix wasn't
promotional or misleading, as had been alleged by a rival company.

U.K.-based Glaxo had distributed the release in June, announcing that
results of a patient trial of Cervarix were being published in the
medical journal The Lancet. The press release said the study showed
that Cervarix provided up to 100% protection against advanced
precancerous lesions caused by the most common types of the human
papillomavirus, or HPV.

Sanofi Pasteur MSD, which markets cervical-cancer vaccine Gardasil in
Europe, subsequently complained to the U.K. Medicines and Healthcare
Products Regulatory Agency, or MHRA, that Glaxo's press release was
misleading and promoted Cervarix by selectively using data from the
study. Sanofi Pasteur MSD is a joint venture of Sanofi-Aventis (SNY)
of France and Merck & Co. (MRK), Whitehouse Station, N.J.

The MHRA, however, announced Tuesday that it didn't consider the Glaxo
press release to be promotional, so it didn't uphold Sanofi Pasteur
MSD's complaint.

"We're pleased and we remain committed to an ethical approach to
marketing," Glaxo spokeswoman Alice Hunt said. A Sanofi spokesman
couldn't immediately be reached.

The European Commission approved Gardasil last year. Sanofi Pasteur
recorded Gardasil sales of EU81 million in the first half of 2007.
Merck markets Gardasil in the U.S., where first-half sales were $723
million.

Glaxo has applied for regulatory approval of Cervarix in the U.S. and
Europe, and hopes to overtake Gardasil despite its expected later
entry to the market.

In a separate case, the MHRA upheld portions of a complaint alleging
that Encysive Pharmaceuticals Inc. (ENCY) displayed misleading
promotional materials about its Thelin drug at a U.K. medical meeting
earlier this year. Encysive agreed to make certain changes in response
to MHRA's decision.

Houston-based Encysive Pharmaceuticals exhibited "promotional stand
panels" for Thelin, a drug to treat pulmonary arterial hypertension,
at the annual meeting of the British Society of Rheumatology in
Birmingham, U.K., in May 2007, according to MHRA. Thelin is approved
for sale in Europe but hasn't yet been approved by the U.S. Food and
Drug Administration.

A rival company, Actelion Ltd. (ATLN.EB) of Switzerland, complained
that the Encysive exhibit promoted an unlicensed dose of Thelin;
promoted the product outside its approved uses; made misleading
comparisons to Actelion's Tracleer drug for pulmonary arterial
hypertension; and used selective safety data to exaggerate the
properties of Thelin.

The MHRA said Tuesday it upheld two aspects of Actelion's complaint.
Encysive acknowledged that the 300-milligram dose of Thelin had been
"mentioned in error, " and agreed to ensure that data on liver
function reflects the balance of evidence in the product's summary of
characteristics. The MHRA also recommended that future Encysive
materials make it clear whether studies were designed to assess
comparative differences between products.

Spokespeople for Encysive and Actelion either couldn't immediately be
reached or declined immediate comment.

Ilena Rosenthal has been using hysteria and scare tactics, to pump up
fear via the tauting of "7" UNPROVEN associated deaths to Gardasil.

She continues to simply not mention and acknowledge, that 250,000 -
290,000 women die each year from Cervical Cancer. 70% of these
cancers are attributed to the HPV virus, which Gardasil would protect
against.

She mentions the 225 mcgs of aluminum in each jab of vaccine, when
there are 4 times that amount in a single serving of spinich. And
even higher amounts of aluminum in other "healthy" foods.

Apparently, Ilena Rosenthal is hoping to get in on the ground floor of
any attorney "head-hunting" capers that attorneys may "require" if yet
another Class Action comes down the road.

It is interesting, that no other countries are reporting "UNPROVEN"
associated deaths with this vaccine.

Ilena Rosenthal appears to be a very effective flak for the Funeral
Industry.



On Sep 12, 2:54 pm, Ilena Rose wrote:
http://ilena-rosenthal.blogspot.comh...-of-cervical-c...

We've been waiting for this time!

Merck has been going whole hog spending billions PRing & advertising
it's Gardasil on every level possible.

His usenet flacks use their scare tactics and trivialize the risks and
unknowns, calling a vastly complicated and complex issue "simple
math."

They are attempting to sell as many of their $120 jabs (advising a
minimum of 3) as possible before the dangers surfaced into the media
and their rival came out to fight for it's right to sell their own
version of a wildly profitable, unproven drug.

Well ... now it's the Giants against each other ... a veritable flack
wonderland. They can start 'double dipping' in the HPV department and
fuel the Vac Maker Wars.

http://money.cnn.com/news/newsfeeds/...709111051DOWJO...

UK Regulator: GSK Cervarix Announcement Wasn't Promotional

September 11, 2007: 10:51 AM EST

LONDON -(Dow Jones)- The U.K.'s drug regulator Tuesday said it
concluded that a GlaxoSmithkline PLC (GSK) press release about the
drug maker's experimental cervical-cancer vaccine Cervarix wasn't
promotional or misleading, as had been alleged by a rival company.

U.K.-based Glaxo had distributed the release in June, announcing that
results of a patient trial of Cervarix were being published in the
medical journal The Lancet. The press release said the study showed
that Cervarix provided up to 100% protection against advanced
precancerous lesions caused by the most common types of the human
papillomavirus, or HPV.

Sanofi Pasteur MSD, which markets cervical-cancer vaccine Gardasil in
Europe, subsequently complained to the U.K. Medicines and Healthcare
Products Regulatory Agency, or MHRA, that Glaxo's press release was
misleading and promoted Cervarix by selectively using data from the
study. Sanofi Pasteur MSD is a joint venture of Sanofi-Aventis (SNY)
of France and Merck & Co. (MRK), Whitehouse Station, N.J.

The MHRA, however, announced Tuesday that it didn't consider the Glaxo
press release to be promotional, so it didn't uphold Sanofi Pasteur
MSD's complaint.

"We're pleased and we remain committed to an ethical approach to
marketing," Glaxo spokeswoman Alice Hunt said. A Sanofi spokesman
couldn't immediately be reached.

The European Commission approved Gardasil last year. Sanofi Pasteur
recorded Gardasil sales of EU81 million in the first half of 2007.
Merck markets Gardasil in the U.S., where first-half sales were $723
million.

Glaxo has applied for regulatory approval of Cervarix in the U.S. and
Europe, and hopes to overtake Gardasil despite its expected later
entry to the market.

In a separate case, the MHRA upheld portions of a complaint alleging
that Encysive Pharmaceuticals Inc. (ENCY) displayed misleading
promotional materials about its Thelin drug at a U.K. medical meeting
earlier this year. Encysive agreed to make certain changes in response
to MHRA's decision.

Houston-based Encysive Pharmaceuticals exhibited "promotional stand
panels" for Thelin, a drug to treat pulmonary arterial hypertension,
at the annual meeting of the British Society of Rheumatology in
Birmingham, U.K., in May 2007, according to MHRA. Thelin is approved
for sale in Europe but hasn't yet been approved by the U.S. Food and
Drug Administration.

A rival company, Actelion Ltd. (ATLN.EB) of Switzerland, complained
that the Encysive exhibit promoted an unlicensed dose of Thelin;
promoted the product outside its approved uses; made misleading
comparisons to Actelion's Tracleer drug for pulmonary arterial
hypertension; and used selective safety data to exaggerate the
properties of Thelin.

The MHRA said Tuesday it upheld two aspects of Actelion's complaint.
Encysive acknowledged that the 300-milligram dose of Thelin had been
"mentioned in error, " and agreed to ensure that data on liver
function reflects the balance of evidence in the product's summary of
characteristics. The MHRA also recommended that future Encysive
materials make it clear whether studies were designed to assess
comparative differences between products.

Spokespeople for Encysive and Actelion either couldn't immediately be
reached or declined immediate comment.